Update on the Management of ABCA4 Retinopathy (Stargardt Disease)
Deepika C Parameswarappa, Dhanashree Ratra, Goura Chattannavar, Srikanta Kumar Padhy · 2026
Read Update on the Management of ABCA4 Retinopathy (Stargardt Disease) by Deepika C Parameswarappa, Dhanashree Ratra, Goura Chattannavar, Srikanta Kumar Padhy (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13315051.txt.
Description
Deepika C Parameswarappa and co-authors update, in a 2026 review, the management of ABCA4 retinopathy, better known as Stargardt disease. It is the most common inherited macular dystrophy, stealing central vision in life when clearance of vitamin A byproducts poisons the retinal pigment layer. No approved therapy alters its course, and care remains supportive, built on low-vision rehabilitation and counseling.
The review surveys how that is beginning to change. The pipeline now attacks the disease at heights. It slows the visual cycle, deploys modified vitamin A that resists toxic clumping, blocks retinol transport, replaces or edits the gene, silences it with antisense drugs, and transplants retinal cells. For end-stage eyes, optogenetic therapy promises independent vision restoration. The authors organize the options by disease stage, discuss which trial endpoints can prove benefit, and argue that combination therapy and matching offer optimism for a condition written off as untreatable.
Catalog record
| CREATOR | Deepika C Parameswarappa, Dhanashree Ratra, Goura Chattannavar, Srikanta Kumar Padhy |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |